Browsing Tag
PET Imaging
6 posts
Telix Pharmaceuticals (TLX) gains European review momentum for TLX101-Px brain cancer imaging candidate
Telix has a glioma imaging gap to fill. Europe’s TLX101-Px review could test whether radiopharma can move beyond prostate cancer.
Could Pixclara become the missing imaging tool in U.S. glioma care after FDA NDA acceptance?
Could Pixclara transform U.S. glioma imaging after FDA NDA acceptance? Explore what Telix Pharmaceuticals Limited’s September catalyst could change next.
Radiopharm Theranostics RAD 101 hits primary endpoint in 90% of brain metastasis patients at second Phase 2b interim analysis
Radiopharm Theranostics RAD 101 achieves 90% PET-MRI concordance in brain metastases Phase 2b trial. Full data due June 2026. Read more.
Telix Pharmaceuticals (ASX: TLX) orders four IBA cyclotrons to build in-house isotope production at RLS radiopharmacy network
Telix (ASX: TLX) orders four IBA Cyclone KIUBE cyclotrons for U.S. RLS radiopharmacy sites. What it means for isotope supply chains. Read more.
PET imaging firm Positron (OTC: POSC) secures $2m to scale operations and pursue FDA clearances
Positron Corporation raises $2M to scale its PET-CT imaging platform and pursue regulatory clearances. Find out what this means for cardiac diagnostics in 2026.
Telix Pharmaceuticals submits NDA for Pixclara to advance brain cancer imaging
Telix Pharmaceuticals Limited (ASX: TLX) has taken a significant step in the realm of neuro-oncology by submitting a…